A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|December 2, 2025
Breaking Down CELEBRATE and POLY-HF: Two Paths to Better Cardiac Care
Fact checked by: Ron Panarotti
Advertisement
In this solo episode, Craig Beavers breaks down new data from the CELEBRATE STEMI (NCT04825743) trial and the POLY-HF (NCT04633005) polypill study. He highlights what these findings could mean for real-world practice, from early antiplatelet strategies to improving adherence and outcomes in heart failure.
Show Notes:
Advertisement
Related to this article
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
4
Can AI Help Predict Drug Shortages?
5